Azenta (AZTA)

• Market cap: $2.19B
• 1 day: -0.07%
• 5 days: -3.01%
• 1 month: -16.87%
• 3 months: -1.71%
• 6 months: -9.41%
• Year to date: -10.57%
• 1 year: -29.33%
• 5 years: 17.18%
• 10 years: 271.68%
• Sector: Industrials
• Industry: Special Industry Machinery

About: Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.

Employees: 3,300

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

12.28% more ownership

Funds ownership: 102.0% [Q3] → 114.29% (+12.28%) [Q4]

8% more capital invested

Capital invested by funds: $2.42B [Q3] → $2.61B (+$193M) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

0% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 51

2% less funds holding

Funds holding: 306 [Q3] → 299 (-7) [Q4]

19% less call options, than puts

Call options by funds: $12.1M | Put options by funds: $15M

24% less repeat investments, than reductions

Existing positions increased: 93 | Existing positions reduced: 123

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $52 16% upside
• Avg. target: $57 27% upside
• High target: $60 34% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

Evercore ISI Group Vijay Kumar 53% 1-year accuracy 25 / 47 met price target	16% upside $52	In-Line Maintained	6 Feb 2025
Needham David Saxon 37% 1-year accuracy 24 / 65 met price target	32% upside $59	Buy Maintained	6 Feb 2025
Stephens & Co. Jacob Johnson 19% 1-year accuracy 3 / 16 met price target	34% upside $60	Overweight Reiterated	2 Jan 2025